356 results about "CD20" patented technology

The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.

The invention discloses application of an anti-CD20 antibody drug conjugate or a drug combination thereof in preparation of a drug for treating diffuse large B-cell lymphoma. The drug combination comprises the anti-CD20 antibody drug conjugate, gemcitabine and oxaliplatin, the anti-CD20 antibody drug conjugate or the drug combination therapy containing the anti-CD20 antibody drug conjugate has a better curative effect compared with the existing clinical second-line standard therapy.

Various embodiments of the invention provide binding molecules for B-lymphocyte antigen (e.g., CD 19 and CD20), including antigen recognizing receptors (e.g., CARs) that target B-lymphocyte antigens (e.g., CD 19 and CD20). Embodiments of the invention also provide cells expressing such binding molecules, therapeutics compositions comprising such cells, and methods for treating diseases or disorders associated with B-lymphocyte antigen (e.g., CD19 and CD20), including a hematologic cancer, an autoimmune disease (e.g., multiple sclerosis and systemic lupus erythematosus).

Provided herein are novel anti-CD20 x anti-CD28 antibodies and methods of using such antibodies for the treatment of B-cell malignancies. Subject anti-CD20 x anti-CD28 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and CD20 on tumor cells. Thus, such antibodies enhance anti-tumor activity at tumor sites. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-CD20 x anti-CD79b antibodies) for the treatment of B-cell malignancies.

The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).

A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20) / anti-cluster of differentiation 3 (CD3) bispecific antibodies.

The invention belongs to the technical field of tumor micro-immune environments, and particularly relates to a kit for detecting a tumor micro-environment, a detection method and application, the kit comprises rare metal element labeled monoclonal antibodies, the rare metal element labeled monoclonal antibodies comprise 115In-CD20, 139La-Histone H3, 142Nd-CD56, 144Nd-CD14, 146Nd-Vimentin, 148Nd-Pan-CK, 151Eu-CD31, 156Gd-CD4, 158Gd-E-Cadrin, 159Tb-CD68, 162Dy-CD8a, 166Er-CD45, 167Er-CD15, 170Er-CD3, 171Yb-CD11c and 209Bi-alpha-SMA, and the rare metal element labeled monoclonal antibodies comprise The invention can be used for simultaneously detecting and researching the quantity, positioning and spatial topological relation of each cell component in a tumor microenvironment, and provides a multi-immunofluorescence detection kit and method for ubiquitous epithelial differentiation-derived tumors based on an imaging mass spectrum flow technique. A plurality of biomarkers can be analyzed at the same time by using multiple immunohistochemical staining and rare earth metal tag signal detection technologies, so that the aim of performing high-dimensional analysis on a tumor microenvironment is fulfilled according to cell composition, functional state and cell-cell space interaction relationship.

A CD20-OR-CD19 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD20-OR-CD19 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD20-OR-CD19 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

The invention belongs to the field of biological medicine, and relates to a pharmaceutical composition of an anti-CD3 * CD20 bispecific antibody, in particular to a liquid preparation and a freeze-dried preparation of the bispecific antibody and medical application of the liquid preparation and the freeze-dried preparation. More specifically, the pharmaceutical composition contains an anti-CD3 * CD20 bispecific antibody, a buffer solution, a stabilizer and a surfactant, the pH value of the pharmaceutical composition is about 4.5-6.5, and the pharmaceutical composition has good stability.

The invention discloses a kit and method for detecting leukemia and lymphoma based on full-spectrum flow cytometry, the kit comprises 25 antibodies, the antibodies are specifically bound with fluorescein respectively, and leukemia and lymphoma are detected through full-spectrum flow cytometry; the 25 kinds of antibodies comprise HLA-DR (human leukocyte antigen-DR), CD38, CD7, CD34, Lambda, CD19, CD64, CD14, CD5, CD123, CD16, CD20, Kappa, CD117, CD13, CD45, CD11b, CD2, CD10, CD8, CD15, CD4, CD3, CD56 and CD33. The kit comprehensively covers development stages of various lines of bone marrow cells, and common abnormal expressions of various leukemia, myelodysplastic syndromes and lymphoma, and can preliminarily screen various leukemia and lymphoma.

Disclosed herein is a composition comprising one or more polynucleic acid molecules comprising a sequence encoding an anti-CD20 CAR, a sequence encoding an anti-CD22 CAR, and a sequence encoding an anti-CD19 CAR. Disclosed herein is a composition comprising one or more polynucleic acid molecules comprising a sequence encoding an anti-CD19 binding domain. Disclosed herein is a composition comprising one or more polynucleic acid molecules comprising a sequence encoding an anti-CD20 binding domain. Further provided herein are pharmaceutical compositions comprising the polynucleic acid molecules, and methods for cancer treatment.

Provided are methods of clinical treatment of Diffuse Large B-cell Lymphoma (for example, relapsed and / or refractory Diffuse Large B-cell Lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with lenalidomide or ibrutinib and lenalidomide.

Provided are multispecific antigen binding proteins (MSAPs), such as trispecific antigen binding proteins (TSAPs or trispecific T cell engagers), that specifically bind to CD20, CD19, and CD3. Also provided are TSAPs or bispecific antigen binding proteins (BSAPs), that specifically bind to CD3 and CD20. Compositions (e.g., pharmaceutical compositions), kits, methods of use (e.g., treating cancer), and methods of making thereof are also provided.

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20 / anti-CD3 bispecific antibody (e.g., mosunetuzumab).

The invention belongs to the technical field of biology, and discloses a nano antibody targeting B cell CD20 and application of the nano antibody. The amino acid sequences of the complementarity determining regions CDR1-CDR3 of the nano antibody are selected from SEQ ID NO.1-9. The nano antibody provided by the invention can be specifically combined with B cells in human blood, so that the B cells generating pathological antibodies are removed. Compared with the traditional antibody, the nano antibody provided by the invention has the advantages of smaller molecular weight, high stability, low cost, easiness in expression and high expression quantity, and is suitable for large-scale production. The nano antibody is combined with the solid-phase carrier, B cells in blood can be cleared in a targeted mode, the number of the B cells in the blood of a patient can be reduced in a short time, the antibody level can be reduced, therefore, the life quality is improved, complications are reduced, and a new treatment choice is provided for the patient who is ineffective or intolerant to traditional treatment.

The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.

The present invention provides an antibody composition for detecting multiple myeloma based on full-spectrum flow cytometry and its application, belonging to the technical field of multiple myeloma detection. The antibody composition includes CD3 antibody, CD20 antibody, HLA-DR antibody, CD8 antibody, CD11b antibody, CD10 antibody, CD71 antibody, CD28 antibody, CD14 antibody, CD13 antibody, Igκ antibody, CD15 antibody, Igλ antibody, CD117 antibody, CD56 antibody, CD45 antibody, CD19 antibody, CD34 antibody, CD138 antibody, CD4 antibody, CD38 antibody, CD22 antibody and CD27 antibody. The kit containing the antibody composition can be applied to a full-spectrum flow cytometer to accurately perform preliminary screening on patients with multiple myeloma.

Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20 / anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.

The invention discloses application of an anti-CD20 antibody drug conjugate or a drug combination thereof in preparation of a drug for treating recurrent or refractory non-Hodgkin lymphoma after receiving at least one standard treatment regimen, and the drug combination comprises the anti-CD20 antibody drug conjugate and at least one therapeutic agent, the anti-CD20 antibody drug conjugate or the drug combination therapy containing the anti-CD20 antibody drug conjugate has a better curative effect compared with the existing clinical second-line standard therapy.

The present invention provides dosing regimens of bispecific antibodies that target both CD3 and CD20 when used in the treatment of lymphoma, such as B cell non-Hodgkin lymphoma (B-NHL).

Provided herein are multispecific antibodies, including trispecific antibodies that bind to CD79b, CD20 and CD3, and bispecific antibodies that bind to CD79b and CD3, and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are isolated antibodies that bind to CD79b and antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided CD79b-specific antibodies or antigen-binding fragments, cells expressing the provided CD79b-specific antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled CD79b-specific antibodies or antigen-binding fragments. In addition, methods of producing and using the provided CD79b-specific antibodies and antigen-binding fragments are described.

Disclosed is a monoclonal antibody that binds human and monkey CD3, or an antigen-binding portion thereof, as well as the use of the antibody or antigen-binding portion thereof in treatment of inflammatory diseases and in preparation of bispecific antibodies. A bispecific antibody against e.g., CD3 and CD20 comprising the antibody or antigen-binding portion thereof of the disclosure, and the use of the bispecific antibody in treatment of diseases such as cancers are also provided.

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of an anti-CD20 / anti-CD3 bispecific antibody.

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas or chronic lymphocytic leukemia). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of mosunetuzumab as a monotherapy or in combination with lenalidomide.

The present invention relates to the combined use of FcyRIIb (CD32B)- and CD20-specific antibodies, in particular to a method of treating a patient having target cells expressing FcyRIIb, the method comprising the combined administration of: (i) an antibody molecule specifically binding to a surface antigen of said target cells, said antibody molecule having an Fc domain capable of binding to FcyRIIb; and (ii) an agent inhibiting or reducing the binding between the Fc domain of said antibody molecule and FcyRIIb, characterized in that the patient is selected on the basis of an elevated level of FcyRIIb expression by his target cells.

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20 / anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.

The present invention relates to anti-CD37antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG, for use as a medicament in combination with anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG. The invention also relates to a novel composition of anti-CD37 antibodies having an Fc-Fc 5 interaction enhancing substitution and anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution. In particular, the invention relates to compositions wherein the anti-CD37 antibody binds human CD37 and the anti-CD20 antibody binds human CD20. The invention also relates to compositions where the composition is a pharmaceutical composition and the use of such compositions in treatment of cancer and other diseases.

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

The invention relates to a marker combination for predicting curative effect of melanoma anti-PD-1 immunotherapy and application of the marker combination. Specifically, more abundant and more accurate biomarkers (S100, CD68, CD3, CD20, PD-L1 and PD-1) related to the curative effect of the melanoma immunotherapy are obtained through co-localization of a plurality of biomarkers and spatial feature analysis, and a prediction model for evaluating the curative effect of the melanoma anti-PD-1 immunotherapy is prepared by using the biomarkers. The model has good sensitivity and specificity, and has a wide application prospect.